Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: The ICE study

Journal of the Peripheral Nervous System

Volumn 15, Issue 3, 2010, Pages 208-215

  Merkies, Ingemar S J ^a   Hughes, Richard A C ^c   Donofrio, Peter ^d   Bril, Vera ^e   Dalakas, Marinos C ^f   Hanna, Kim ^g   Hartung, Hans Peter ^h   Latov, Norman ⁱ   Van Doorn, Pieter A ^b   Deng, Chunqin ^g  

^a Infection and Immunology   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g Talecris Biotherapeuticsm Inc   (United States)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CIDP; disability; impairments; intravenous immunoglobulin; quality of life; randomized trial

Indexed keywords

HUMAN IMMUNOGLOBULIN; PLACEBO;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; GRIP STRENGTH; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PATIENT PARTICIPATION; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SHORT FORM 36; TREATMENT FAILURE;

DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HAND STRENGTH; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; NEURAL CONDUCTION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; QUALITY OF LIFE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78349282601     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2010.00274.x     Document Type: Conference Paper

References (19)

1. Aaronson NK, (1988). Quality of life: what is it? How should it be measured? Oncology 2: 69-76.
2. Boukhris S, Magy L, Khalil M, Sindou P, Vallat JM, (2007). Pain as the presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neurol Sci 254: 33-38.
3. Bril V, Katzberg H, Donofrio P, Banach M, Dalakas MC, Deng C, Hanna K, Hartung HP, Hughes RA, Latov N, Merkies IS, Van Doorn PA, on behalf of the ICE Study Group (2009). Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 39: 448-455.
4. Cooke JF, Orb A, (2003). The recovery phase in Guillain-Barre syndrome: moving from dependency to independence. Rehabil Nurs 28: 105-108, 130.
5. Doering S, Henze T, Schussler G, (1993). Coping with illness in myasthenia gravis. Nervenartz 64: 640-647.
6. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC, (1994). A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36: 838-845.
7. Garssen MP, Bussmann JB, Schmitz PI, Zandbergen A, Welter TG, Merkies IS, Stam JH, Van Doorn PA, (2004). Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology 63: 2393-2395.
8. Harbo T, Andersen H, Overgaard K, Jakobsen J, (2008). Muscle performance relates to physical function and quality of life in long-term chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 13: 208-217.
9. Hughes R, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, Van Doorn PA, on behalf of the ICE Study Group (2008). Intravenous immune globulin (10% caprylate/chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurol 7: 136-144.
10. Lunn MP, Leger JM, Merkies IS, Van den Bergh P, Van Schaik IN, on behalf of the Inflammatory Neuropathy Consortium (2008). 151st ENMC International Workshop: Inflammatory Neuropathy Consortium 13th-15th April 2007, Schiphol, The Netherlands. Neuromuscul Disord 18: 85-89.
11. Merkies ISJ, (2001). Evaluation of scales and measurement instruments in immune-mediated polyneuropathies. Thesis, Rotterdam, The Netherlands. ISBN: 90-9014393-8.
12. Merkies IS, Lauria G, (2006). 131st ENMC International workshop: selection of outcome measures for peripheral neuropathy clinical trials. 10-12 December 2004, Naarden, The Netherlands. Neuromuscul Disord 16: 149-156.
13. Merkies IS, Schmitz PI, Van Der Meche FG, Samijn JP, Van Doorn PA, (2002). Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 59: 84-91.
14. Merkies IS, Schmitz PI, Van Der Meche FG, Samijn JP, Van Doorn PA, (2003). Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 74: 99-104.
15. Merkies IS, Bril V, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung H-P, Hughes RA, Latov N, Van Doorn PA, on behalf of the ICE study group (2009). Health-related quality-of-life improvements in CIDP with immune globulin IV 10%. The ICE Study. Neurology 72: 1337-1344.
16. Molenaar DS, Vermeulen M, De Visser M, De Haan R, (1999). Impact of neurologic signs and symptoms on functional status in peripheral neuropathies. Neurology 52: 151-156.
17. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD, (2000). Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19: 1059-1079.
18. Ware JE Jr, Kosinski M, Keller SD, (1994). SF-36 Physical and Mental Health Summary Scales: A User's Manual. The Health Assessment Lab, New England Medical Center, Boston.
19. World Health Organization (2002). Towards a Common Language for functioning, Disability and Health ICF. Available at:. (Accessed 2009 October 14).